Analyst Upgrades

• Expedia (EXPE) to buy from hold at Citigroup.
• Weatherford (WFT) to outperform from market perform at Wells Fargo.
• Abercrombie & Fitch (ANF) to buy from neutral at BofA/Merrill.
• MDC Holdings (MDC) to outperform from neutral at Credit Suisse.
• AutoNavi (AMAP) to buy from neutral at Goldman.
• Ciena (CIEN) and Nvidia (NVDA) to neutral from underweight at JPMorgan.
• Canadian Pacific (CP) to outperform from market perform at Raymond James.
• First Midwest (FMBI) and Quiksilver (ZQK) to buy from hold at Jefferies.
• Sonic (SONC) to neutral from negative at Susquehanna.
• MIPS Technologies (MIPS) to buy from hold at Benchmark Co.
• Arrow Electronics (ARW) and Avnet (AVT) to buy from hold at Stifel Nicolaus.

Continue reading Analyst Calls: ANF, BBBY, CIEN, CP, EXPE, ICE, NVDA, QCOM, SONC ...

Analyst Calls: ANF, BBBY, CIEN, CP, EXPE, ICE, NVDA, QCOM, SONC ... originally appeared on BloggingStocks on Tue, 08 Mar 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Chesapeake (CHK) to buy from hold at Canaccord.
• Biogen (BIIB) and Regeneron (REGN) to outperform from sector perform at RBC Capital.
• Caribou Coffee (CBOU) to outperform from neutral and Encore Energy (ENP) to neutral from underperform at RW Baird.
• Fluor (FLR) to market perform from underperform at BMO Capital.
• Hornbeck Offshore (HOS) to conviction buy from neutral at Goldman.
• Saks (SKS) and Zale (ZLC) to neutral from underperform at BofA/Merrill.

Continue reading Analyst Calls: BIIIB, CBOU, CELG, CHK, CIEN, HOS, LULU, RHT, SKS, ZLC ...

Analyst Calls: BIIIB, CBOU, CELG, CHK, CIEN, HOS, LULU, RHT, SKS, ZLC ... originally appeared on BloggingStocks on Thu, 24 Feb 2011 11:30:00 EST. Please see our terms for use of feeds.

"As tradition holds, Celgene (CELG) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene's ongoing plans to become a world-wide company and expansion into global markets," reports John McCamant.

The biotech specialist and editor of The Medical Technology Stock Letter explains, "They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs.

"Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition.

Continue reading Celgene (CELG): A Biotech Takeover Target?

Celgene (CELG): A Biotech Takeover Target? originally appeared on BloggingStocks on Tue, 15 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: The DJIA Passed 11,000 Once Again! (NBG, PALM, CELG, WMT, MEE, LCC)

Closing Bell: The DJIA Passed 11,000 Once Again! (NBG, PALM, CELG, WMT, MEE, LCC) originally appeared on BloggingStocks on Fri, 09 Apr 2010 16:20:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
• JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
• Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
• Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
• Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
• Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ... originally appeared on BloggingStocks on Fri, 12 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Continue reading Celgene Blood Cancer Drug Found Effective

Celgene Blood Cancer Drug Found Effective originally appeared on BloggingStocks on Fri, 18 Dec 2009 13:00:00 EST. Please see our terms for use of feeds.

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company.

Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA.

"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others involved in stem cell research.

Continue reading Celgene (CELG): Bet on biotech for 'offense and defense'

Celgene (CELG): Bet on biotech for 'offense and defense' originally appeared on BloggingStocks on Tue, 27 Oct 2009 11:20:00 EST. Please see our terms for use of feeds.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Celgene (CELG): Cancer progress boosts biotech originally appeared on BloggingStocks on Wed, 19 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Continue reading Time to scoop up some shares of Celgene

Time to scoop up some shares of Celgene originally appeared on BloggingStocks on Fri, 19 Jun 2009 17:00:00 EST. Please see our terms for use of feeds.

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

Continue reading Celgene (CELG): Selloff creates opportunity

Celgene (CELG): Selloff creates opportunity originally appeared on BloggingStocks on Mon, 06 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

"Celgene (NASDAQ: CELG) reported their fourth quarter and year end numbers which showed strong revenue growth." observes biotech sector expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "We remain excited about CELG's growth prospects and management's ability to deliver the goods.

"Total revenue for the quarter grew 50% to $623 million, with the primary driver being Revlimid sales of $369.4 million. Sales of their two other drugs, Thalomid and Vidaza generated $126.8 million and 69.7 million, respectively.

Continue reading Celgene (CELG): Strong growth in biotech

Celgene (CELG): Strong growth in biotech originally appeared on BloggingStocks on Mon, 23 Feb 2009 11:40:00 EST. Please see our terms for use of feeds.

Celgene (NASDAQ: CELG), a biopharmaceutical company, closed at $50.34. CELG is scheduled to announce Q4 EPS on January 29. CELG February and March option implied volatility of 49 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Genzyme (NASDAQ: GENZ) closed at $68.20. GENZ is expected to report Q4 EPS on February 11. Robert W Baird has an $87 price target on GENZ. GENZ February option implied volatility of 40 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Gilead Sciences (NASDAQ: GILD), a biopharmaceutical company, is scheduled to report Q4 EPS on January 27. GILD February option implied volatility of 46 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options Update: Biopharmaceuticals' volatility flat into EPS originally appeared on BloggingStocks on Tue, 27 Jan 2009 08:00:00 EST. Please see our terms for use of feeds.

From TheStreet.com Network

• Pfizer in Talks to Acquire Wyeth
• Pfizer to Slash Up to 2,400 Sales Jobs

Pfizer's (NYSE: PFE) (Cramer's Take) moves suddenly make sense. You lay off your scientists, you buy the better group at Wyeth (NYSE: WYE) (Cramer's Take) , you get Wyeth's franchise and you slash the sales budget, and voila, you have growth.

That's the greatness of the pharma industry. You need mergers, especially when Obama has made it clear that he's not going to be in the camp of stifling generic competition, of which Pfizer faces the brunt of.

It is why I recommended Forest Labs (NYSE: FRX) (Cramer's Take) last night -- believe me, that's the cheapest. I own Bristol-Myers (NYSE: BMY) (Cramer's Take) because BMY looks like Wyeth with a bigger dividend and a great cancer franchise.

Celgene (NASDAQ: CELG) (Cramer's Take) too -- Celgene was approached not that long ago when it was much higher. CELG's another way to replenish.

Continue reading Cramer on BloggingStocks: Pfizer's Wyeth bid is obvious in retrospect

Cramer on BloggingStocks: Pfizer's Wyeth bid is obvious in retrospect originally appeared on BloggingStocks on Fri, 23 Jan 2009 10:15:00 EST. Please see our terms for use of feeds.

Merck (NYSE: MRK) is recently trading at $25.54 in pre-open trading, below its close of $26.46. MRK expects 2009 top-line growth will be offset by the effects of a volatile global economy. MRK December option implied volatility of 70 is above its 26-week average of 43 according to Track Data, suggesting larger price movement.

Allergan (NYSE: AGN) discovers and develops specialty pharmaceutical products. AGN closed at $36.20. AGN's Latisse (Bimatoprost for eyelash growth) PDUFA date is expected in mid-year 2009. AGN December option implied volatility is at 76, July is at 55; above its 26-week average of 50 according to Track Data, suggesting larger price movement.

Celgene (NASDAQ: CELG), a biopharmaceutical company, closed at $52.60. CELG's Revlimid's (non-Hodgkin's lymphoma treatment) incremental Phase 3 data on Revlimid in first line multiple myeloma is expected at the American Society of Hematology (ASH) meeting on December 6 to December 9. CELG December option implied volatility of 75 is above its 26-week average of 53 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options Update: Merck volatility elevated into lower 2009 outlook; AGN, CELG originally appeared on BloggingStocks on Thu, 04 Dec 2008 08:48:00 EST. Please see our terms for use of feeds.

"The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer.

In The Dave Dyer Newsletter, he explains, "That is why Celgene (NASDAQ: CELG) is an excellent choice in this economy." Here's his look at this "recession-resistant" company.

"Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt. Revlimid is their blockbuster drug with multi-billion dollar potential. It was first approved by the FDA in 2005, and it has many good years of patent protection ahead of it.

"Revlimid delays the onset of progression of deadly diseases -- leprosy and multiple myeloma. No wonder it is worth $6,000 per month. It is a close derivative of their other drug Thalomid. This drug was used by another company about 50 years ago to treat morning sickness in pregnant women and caused numerous birth defects.

"Despite a recession, we believe that demand for its products will remain strong. For example, if you have multiple myeloma, you would probably do just about anything before missing a payment for your monthly dose of Revlimid.

Continue reading Celgene (CELG): Blockbuster potential?

Celgene (CELG): Blockbuster potential? originally appeared on BloggingStocks on Thu, 27 Nov 2008 14:30:00 EST. Please see our terms for use of feeds.

For a bullish hedged play on this stock, I would consider an August bull-put credit spread below the $55 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 5.3% return in just seven weeks as long as CELG is above $55 at August expiration. Celgene would have to fall by more than 17% before we would start to lose money. Learn more about this type of trade here.

Continue reading Celgene (CELG) lifted by TV analyst coverage

Celgene (CELG) lifted by TV analyst coverage originally appeared on BloggingStocks on Tue, 01 Jul 2008 14:37:00 EST. Please see our terms for use of feeds.

Celgene (NASDAQ: CELG), a biopharmaceutical company with a market cap of $$26 billion, was up $1.51 to $60.80 in pre-open trading.

Cowen says "ECOG Revlimid Study-Interesting Post Hoc Analysis Shows Promising Survival rates With Long-Term Use in The Elderly."

CELG over all option implied volatility of 39 is below its 26-week average of 43 according to Track Data, suggesting decreasing price risk.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update: Celgene volatility at low end of range into positive data originally appeared on BloggingStocks on Fri, 16 May 2008 09:40:00 EST. Please see our terms for use of feeds.

Two leading advisors with noted expertise in the biotech sector have both been long-term fans of Celgene (NASDAQ: CELG), both holding the stock in their respective model portfolios.

Here, Nate Pile, editor of Nate's Notes, and John McCamant, editor of The Medical Technology Stock Letter, each take a look at the encouraging prospects for this biotechnology firm.

Nate Pile explains, "Now that the Pharmion merger is behind us, it appears that investors are once again
recognizing Celgene for what it is - namely, one of the premier stories in the biopharmaceutical space.

"As I have said a number of times before, if I could only own one biotech stock for the next ten years, Celgene would be it... and I encourage you to make it a 'first choice' for your portfolio as well!

"The stock is likely to exhibit its usual volatility around the company's upcoming earnings report, but I encourage you to take advantage of any sell-off that may occur to aggressively add to your position in this market leader. CELG is now considered a strong buy under $60 and a buy under $68."

John McCamant states, "Celgene had some good news of late on the thalidomide front. The company has received approval of the application to expand the drug's label to treat newly diagnosed multiple myeloma (MM) patients in Australia.

Continue reading Biotech experts bet on Celgene (CELG)

Biotech experts bet on Celgene (CELG) originally appeared on BloggingStocks on Mon, 05 May 2008 11:35:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• While bank stocks aren't exactly hot, they triggered yesterday's rally because when J.P. Morgan Chase & Co (NYSE: JPM) and Wells Fargo & Company (NYSE: WFC) reported, there were no unexpected surprises, according to the Wall Street Journal's "Heard on the Street". The ups and downs in the sector are expected to continue.
• According to people familiar with the matter, the Wall Street Journal reported that Yahoo! Inc (NASDAQ: YHOO) may be moving closer to outsourcing its search advertising to Google Inc (NASDAQ: GOOG) after an initial test yielded what they considered to be positive results.

• The New York Times reported that AT&T Inc (NYSE: T) is planning today to make an announcement that they will gift $100M to improve the skills of the nation's work force and fight the problem of high school dropouts.

• Celgene Corporation (NASDAQ: CELG) is best known for its blockbuster drug Revlimid which is used treat multiple myeloma, a cancer which attacks blood and bones. For patients, it can prolong their lives about 2.9 years, or longer, according to Investor's Business Daily's "The New America".

Newspaper wrap-up: Bad news for banks, but it could have been worse originally appeared on BloggingStocks on Thu, 17 Apr 2008 09:15:00 EST. Please see our terms for use of feeds.